abrdn plc — Full Portfolio

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersRiverVest Venture PartnersYsios CapitalEight Roads Ventures+4 more

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more

Atalanta is a mathematical AI company that provides software verification and formal methods capabilities to ensure provably correct decision-making in complex systems for high-stakes missions in energy, space, and defense sectors.

AI & Machine LearningDeep TechDefense Tech

Jonathan Ring(Founder)in

Co-investorsFelicis VenturesEQT Life SciencesF-Prime Capital

Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases.

BiotechHealthtech

Co-investorsF-Prime CapitalNovartis Venture FundRiverVest Venture PartnersSanofi VenturesEQT Life Sciences

Qlaris Bio is a clinical-stage biotechnology company developing therapies for ophthalmology conditions.

BiotechMedical DevicesDedham, US

Thurein Htoo(Executive Officer, Director)Fred Guerard(President & Chief Executive Officer)Barbara Wirostko(Executive Officer)

BoardWende Hutton(Director)inRonald M. Hunt(Director)Andrew Danielson(Director)

Co-investorsCanaan PartnersCorrelation VenturesMayo Clinic VenturesNew Leaf Venture Partners

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)

BoardArjun Goyal(Director)inOtello Stampacchia(Director)inFrancesco Draetta(Director)in

Co-investorsAndreessen HorowitzVida VenturesBiotechnology Value FundForesite CapitalHillhouse InvestmentOmega Funds+1 more

Titanbay provides a platform for launching and operating private markets fund structures, including Luxembourg vehicles (master, feeder, ELTIF, SMA) and the UK LTAF, with an in-house AIFM.

Enterprise SoftwareFintechSaaS

Co-investorsMotive Partners